Loading
A phase 2/3 trial of cAPOX (capecitabine, oxaliplatin), fruquintinib and tislelizumab in colorectal cancer, run by Peking University Cancer Hospital & Institute, not yet recruiting.
Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer is a phase 2/3, randomised interventional study registered as NCT06443671 by Peking University Cancer Hospital & Institute, with a registry enrolment figure of 132 participants, started 2024-06-01 and due to reach its primary completion in 2026-06-01. Interventions recorded: CapeOX; Fruquintinib and Tislelizumab combined with mCapeOX. Conditions listed: Rectal Cancer. Primary outcome: Pathological complete response(pCR) rates. Colorectal eligibility wording from the registry: "* Histologically confirmed rectal adenocarcinoma; Immunohistochemistry suggests pMMR, or PCR suggests MSS type patients;". Sites: China. No results are recorded here; the registry entry is the source.
Shares Fruquintinib, Tislelizumab, Anti-angiogenic therapy, Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Tislelizumab, Anti-angiogenic therapy, Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Tislelizumab, Anti-angiogenic therapy, Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Platinum agents, Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Fruquintinib, Anti-angiogenic therapy, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.